Physician profile
Danielle Stakes
NPI 1871295873
$796.79
in general payments reported to CMS, 2019-2025
10 companies · $400 in 2025
The $400 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $397 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $796.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $256.74 | 2024 | Farxiga, Airsupra |
| Abbvie INC. | $204.81 | 2024-2025 | Vraylar |
| Glaxosmithkline, LLC. | $159.70 | 2025 | Penmenvy, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.72 | 2025 | Ofev |
| Exact Sciences Corporation | $36.41 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $19.15 | 2025 | |
| Novo Nordisk INC | $18.06 | 2025 | Wegovy |
| Ucb, INC. | $16.13 | 2024 | Bimzelx |
| Merck Sharp & Dohme LLC | $16.07 | 2025 | Vaxneuvance, Enflonsia, Capvaxive |
| Novartis Pharmaceuticals Corporation | $16.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Stakes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.